Revised forecast
Fiscal year ending March 2027 · Full yearThe bar length represents the relative magnitude of change, based on the item that changed the most in this document.
The company expects growth in its data health-related services and data utilization services, higher productivity through the use of AI, lower fixed costs, and improved profitability resulting from business structure improvements.
Loss on valuation of investment securities: ¥59.996 million; loss on sale of shares of an affiliated company: ¥1.658 million; loss on disposal of noncurrent assets: ¥15.780 million; office relocation expenses: ¥2.479 million; total extraordinary losses: ¥79.913 million
| Item | Details |
|---|---|
| Net Sales | Not disclosed → ¥6,000 million（16.7%） |
| Operating profit | Not disclosed → ¥400 million |
| Ordinary income | Not disclosed → ¥380 million |
| Profit attributable to owners of the parent | Not disclosed → ¥260 million（△3.0%） |
| Net income per share | Not disclosed → 20.49 yen and sen |
| Fiscal Period Covered | Fiscal year ending March 2027 |
| Period Covered | Full year |
| Previous-period results | Actual results for the fiscal year ended March 2026: revenue of ¥5,141 million, operating profit of ¥22 million, ordinary profit of ¥10 million, net income attributable to owners of the parent of ¥267 million, and net income per share of ¥21.12 |
| Reason for the revision | The company expects growth in its data health-related services and data utilization services, higher productivity through the use of AI, lower fixed costs, and improved profitability resulting from business structure improvements. |
| Details and amount of extraordinary loss | Loss on valuation of investment securities: ¥59.996 million; loss on sale of shares of an affiliated company: ¥1.658 million; loss on disposal of noncurrent assets: ¥15.780 million; office relocation expenses: ¥2.479 million; total extraordinary losses: ¥79.913 million |
| Consolidated / non-consolidated | Consolidated |
Items this document does not state (2)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Revenue increased as orders and transactions expanded in the data health-related services and data utilization services businesses. In addition, progress was made in reducing fixed costs, including depreciation and amortization, improving operational efficiency, and optimizing staffing. Net income attributable to owners of the parent was also affected by the ¥59 million loss on valuation of investment securities, as well as a ¥330 million extraordinary gain resulting from a subsidiary receiving debt forgiveness from the parent company.